» Articles » PMID: 11686490

Talampanel, a Novel Noncompetitive AMPA Antagonist, is Neuroprotective After Traumatic Brain Injury in Rats

Overview
Journal J Neurotrauma
Publisher Mary Ann Liebert
Date 2001 Nov 1
PMID 11686490
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Talampanel [(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3] benzodiazepine] is an orally active noncompetitive antagonist of the AMPA subtype of glutamate excitatory amino acid receptors. The purpose of this study was to determine whether treatment with talampanel would protect in a rat model of traumatic brain injury (TBI). Twenty-four hours prior to TBI, a fluid-percussion interface was positioned parasagittally over the right cerebral cortex. On the following day, fasted rats were anesthetized with 3% halothane, 70% nitrous oxide, and a balance of oxygen; mechanically ventilated and physiologically regulated; and subjected to right parieto-occipital parasagittal fluid-percussion injury (1.5-2.0 atm). The agent (talampanel, bolus infusion of 4 mg/kg followed by infusion of 4 mg/kg/h over 72 h) or vehicle was administered i.v. starting at either 30 min or 3 h after trauma. Seven days after TBI, brains were perfusion-fixed, coronal sections at various levels were digitized, and contusion areas were measured. Treatment with talampanel, when instituted 30 min after trauma, significantly reduced total contusion area compared to vehicle-treated rats (0.54 +/- 0.25 vs. 1.79 +/- 0.42 mm2, respectively). When talampanel treatment was begun at 3 h, the neuroprotective effect of the drug was lost. In addition, treatment with talampanel starting at 30 min significantly attenuated neuronal damage in all three subsectors of the hippocampal CA1 sector compared to vehicle-treated rats (normal-neuron counts, right (ipsilateral) medial CA1: 80.3 +/- 2.0 [talampanel] vs. 66.3 +/- 2.1 [vehicle] (mean +/- SEM); middle CA1: 71.5 +/- 2.0 vs. 60.3 +/- 2.2; lateral CA1: 74.5 +/- 3.0 vs. 63.0 +/- 3.2, respectively). By contrast, when talampanel treatment was begun at 3 h, normal pyramidal-neuron counts were almost identical in both groups. Our findings document that talampanel therapy instituted 30 min after trauma significantly reduces histological damage.

Citing Articles

Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders.

Brogi S, Campiani G, Brindisi M, Butini S ACS Med Chem Lett. 2019; 10(3):228-236.

PMID: 30891118 PMC: 6421537. DOI: 10.1021/acsmedchemlett.8b00450.


Therapeutic strategies to target acute and long-term sequelae of pediatric traumatic brain injury.

Huh J, Raghupathi R Neuropharmacology. 2018; 145(Pt B):153-159.

PMID: 29933010 PMC: 6309300. DOI: 10.1016/j.neuropharm.2018.06.025.


Preclinical Models of Traumatic Brain Injury: Emerging Role of Glutamate in the Pathophysiology of Depression.

ONeil D, Nicholas M, Lajud N, Kline A, Bondi C Front Pharmacol. 2018; 9:579.

PMID: 29910733 PMC: 5992468. DOI: 10.3389/fphar.2018.00579.


Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

de la Tremblaye P, ONeil D, LaPorte M, Cheng J, Beitchman J, Thomas T Neurosci Biobehav Rev. 2017; 85:160-175.

PMID: 28576511 PMC: 5709241. DOI: 10.1016/j.neubiorev.2017.05.022.


Molecular mechanisms of cognitive dysfunction following traumatic brain injury.

Walker K, Tesco G Front Aging Neurosci. 2013; 5:29.

PMID: 23847533 PMC: 3705200. DOI: 10.3389/fnagi.2013.00029.